^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TIM-3 inhibitor

    Related drugs:
    Associations

    News

    Trials
    3ms
    Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies (clinicaltrials.gov)
    P1/2, N=61, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)
    3ms
    D9571C00001: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=45, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    sabestomig (AZD7789)
    4ms
    TQB2618-AK105-Ib-04: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov)
    P1, N=29, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jun 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns
    Trial termination • Trial primary completion date
    |
    Focus V (anlotinib) • Anniko (penpulimab) • TQB2618
    4ms
    Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P2, N=176, Active, not recruiting, Incyte Biosciences International Sàrl | Trial completion date: Jun 2025 --> Jul 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)
    5ms
    TQB2618-AK105-Ib-03: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=34, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=75 --> 34 | Trial completion date: Dec 2024 --> Mar 2025 | Recruiting --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Anniko (penpulimab) • TQB2618
    5ms
    First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. (PubMed, Oncologist)
    In this heavily pretreated population, no DLTs were reported and modest efficacy was exhibited. A 400-mg Q2W dose was selected for phase II studies investigating INCAGN02390 as part of combination immunotherapies for advanced cancers.
    P1 data • Journal
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    verzistobart (INCAGN2390)
    10ms
    A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=206, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    10ms
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=114, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    11ms
    TRICK-MCC: Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, University of Washington | N=20 --> 12 | Trial completion date: Dec 2029 --> Apr 2027 | Trial primary completion date: Dec 2029 --> Jan 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)
    11ms
    An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov)
    P1/2, N=92, Terminated, Bristol-Myers Squibb | Trial completion date: Apr 2025 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Aug 2024; Business objectives have changed
    Trial completion date • Trial termination • Trial primary completion date
    |
    Opdivo (nivolumab)
    11ms
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=114, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=358 --> 114
    Enrollment closed • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    12ms
    D9571C00001: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, AstraZeneca | Phase classification: P1/2 --> P1
    Phase classification
    |
    sabestomig (AZD7789)